Patent ID: 11925613
Assignee: CANCER PREVENTION PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of producing a single dosage unit tablet comprising (a) about 375 mg of eflornithine hydrochloride monohydrate, (b) about 75 mg of sulindac, and (c) about 1 to about 1.5 weight percent magnesium stearate comprising:
(a) pre-mixing the sulindac and a first excipient to form a first mixture;
(b) mixing the first mixture with a second mixture comprising eflornithine hydrochloride monohydrate and a second excipient to form a blend;
(c) screening the blend to form a granulated blend;
(d) adding magnesium stearate to the granulated blend to obtain a final blend; and
(e) applying a compression force to the final blend to form the tablet.